Matthew W. Foehr
Insider at Ligand Pharmaceuticals; President and CEO at OmniAb; Director at Viking Therapeutics. Based in Emeryville, California.
- Rank
- 1495th of 14,452
- Companies held
- 3
- Largest holding
- LGND, 74.4% of total
- Latest SEC filing
- Apr 7, 2026
What the $100M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals LGND Common Stock | Directly | 259,986 split-adjusted | $286.94 | $74.6M | 74.4% | Form 4, Nov 1, 2022 |
| OmniAb OABI Common Stock | Directly | 4,420,492 | $5.03 | $22.2M | 22.2% | Form 4, Apr 7, 2026 |
| Viking Therapeutics VKTX Common Stock, par value $0.00001 per share | Directly | 135,186 | $25.84 | $3.5M | 3.5% | Form 4, Jan 2, 2026 |
Share counts are the amounts Matthew W. Foehr reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 1492 | Veronique Lecault Chief Operating Officer, AbCellera Biologics | $101M |
| 1493 | David J. Rosa Chief Executive Officer (CEO), Intuitive Surgical. Sunnyvale, CA | $101M |
| 1494 | Glenn Darrel Sanford CEO and Chairman of the Board, AGNT. Bellingham, WA | $100M |
| 1495 | Matthew W. Foehr Insider, Ligand Pharmaceuticals. Emeryville, CA | $100M |
| 1496 | Michael Gonnella Chief Financial Officer, Pershing Square. New York, NY | $100M |
| 1497 | Anne E. White EVP & Pres, Lilly Neuroscience, Eli Lilly and. Indianapolis, IN | $100M |
| 1498 | Gregory E. Johnson Executive Chairman, Franklin Templeton. San Mateo, CA | $100M |
Other Ligand Pharmaceuticals insiders
All LGND insiders- John L. Higgins$120MDirector. #1162 overall
- Todd C. Davis$57.2MChief Executive Officer. #1694 overall
- Jason Aryeh$31.7MDirector. #3496 overall
- Matthew E. Korenberg$14.6MPresident & COO. #6391 overall
- Sunil Patel$13.3MInsider. #6660 overall
- John W. Kozarich$12.1MDirector. #7620 overall
Questions
How much stock does Matthew W. Foehr own?
Matthew W. Foehr holds $100,328,595 in listed stock based on SEC filings and current prices, mostly Ligand Pharmaceuticals (LGND). That ranks 1495th on the Stock Rich List.
Is this Matthew W. Foehr's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Matthew W. Foehr last buy or sell stock?
The most recent open-market trade on file is a sale of 19,244 OABI shares on Apr 7, 2026 at $1.49.